WHO预认证单位第三次邀请糖尿病治疗药品生产商提交评估意向书
3rd Invitation to Manufacturers of medicinal products for management of diabetes to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit
WHO将人胰岛素及胰岛素类似物评估意向邀请更新并更名为糖尿病治疗药品邀请，第三次邀请生产商提交产品评估意向书。新增速效胰岛素类似物注射液100 IU/mL的10 mL西林瓶和3 mL卡式瓶规格，以及司美格鲁肽注射液，具体信息见意向书文件。此次更新源于WHO非传染性疾病和精神卫生部门的请求。
News
11 May, 2026 - 00:12 (CEST)
Announcement
The Invitation to Manufacturers of human insulin and insulin analogues was recently updated and renamed as Invitation to Manufacturers of medicinal products for management of diabetes to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit.
The EOI was updated following a request by the WHO Noncommunicable diseases and Mental Health Department. In particular, the following medicines were added:
- Rapid-acting insulin analogues injection solution 100 IU/ mL in 10 mL vial and 3 mL cartridge
- Semaglutide, injection solution (details in the EOI)
来源：WHO 药品预认证与检查动态 · extranet.who.int